Outpatient Surgery Magazine, providing current information on Surgical Services, Surgical Facility Administration, Outpatient Surgery News and Trends, OR Excellence and more.
Issue link: http://outpatientsurgery.uberflip.com/i/880034
O C T O B E R 2 0 1 7 O U T P A T I E N TS U R G E R Y. N E T 1 9 work through the reconstituting process. The hands-on practice gave them a real sense of how the process works and the coordination that's needed among team members to prepare the drug for administration. With additional guidance from the MHAUS expert, we maintained clear communication and maintained a good pace, and we're confident we can match our performance during a real-life event. After the drill, discuss what worked, what didn't, and how to address areas of needed improvement. Also dis- tribute a post-evaluation test identical to the quiz your staff took before the educational sessions and drill. If my staff's performance is any indi- cation, you'll likely find that their knowledge of MH and how to respond to emergencies will improve across the board. Always be prepared The rarer the event, the more important simulat- ed drills are for response Important Safety Information The use of The use of Revonto in the management of malignant hyperthermia crisis is not a substitute for previously known supportive measures. These measures must be individualized, but it will usually be necessary to discontinue the suspect triggering agents, attend to increased oxygen requirements, manage the metabolic acidosis, institute cooling when necessary, monitor urinary output, and monitor for electrolyte imbalance. Patients who receive i.v. dantrolene sodium preoperatively should have vital signs monitored. If patients judged malignant hype If patients judged malignant hyperthermia susceptible are administered dantrolene sodium preoperatively, anesthetic preparation must still follow a standard malignant hyperthermia susceptible regimen, including the avoidance of known triggering agents. Monitoring for early clinical and metabolic signs of malignant hyperthermia is indicated because attenuation of malignant hyperthermia, rather than prevention, is possible. Despite initial satisfacto Despite initial satisfactory response to i.v. dantrolene there have been reports of fatality, which involve patients who could not be weaned from dantrolene after initial treatment. The administration of i.v. dantrolene is associated with loss of grip strength and weakness in the legs, as well as drowsiness and dizziness. There have been reports of thrombophlebitis following administration of intravenous dantrolene. Tissue necrosis secondary to extravasation has been reported. Injection site reactions (pain, erythema, swelling), commonly due to extravasation, have been reported. Fatal and non-fatal liver disorders of an idiosyncratic or hypersensitivity type may occur with dantrolene sodium therap liver disorders of an idiosyncratic or hypersensitivity type may occur with dantrolene sodium therapy. To report SUSPECTED ADVERSE REACTIONS contact US WorldMeds at 1-888-900-8796 or MEDWATCH at 1-800-FDA-1088 (1-800-332-1088) or http://www.FDA.gov/medwatch/. To see the full prescribing information visit www.revonto.com. © 2017. US WorldMeds, LLC. Revonto is a registered trademark of US WorldMeds, LLC. REV-P91-0217 ® 36 month shelf life* Ready to administer in 20 seconds † Are You Prepared for a CRISIS? Visit www.revonto.com or call (877) 411-USWM (8796) to learn more and to see the full Prescribing Information. *from the date of manufacture † or until solution is clear